HAEMONETICS CORP

Haemonetics Corporation has filed its Definitive Proxy Statement for the 2026 Annual Meeting of Shareholders, scheduled for July 24, 2026. The meeting agenda includes the election of eight directors, an advisory vote on executive compensation, ratification of the independent auditor, and approval of amendments to the company's Long-Term Incentive Compensation Plan and Employee Stock Purchase Plan. The company highlights strong fiscal 2026 performance and governance practices.

Haemonetics Corporation announced a change to its financial reporting segment structure, effective with the first quarter of fiscal year 2027. The company will transition from three to two reportable segments, combining the Plasma and Blood Center segments into a new 'Apheresis' segment and renaming the Hospital segment to 'MedSurg'. This restructuring aims to better align external financial reporting with how the company manages its business and allocates resources. A supplemental presentation with recast historical financial data and fiscal year 2027 guidance has been posted for comparability.

Haemonetics, a global medical technology company, provided an overview of its three principal reporting segments: Plasma, Blood Center, and Hospital. The company focuses on Plasma and Hospital for growth, noting recent FDA clearances for its NexSys PCS Plasma Collection System with Persona PLUS technology and an expanded indication for the VASCADE MVP XL vascular closure system. In fiscal 2025, the company divested its Whole Blood product line to align resources with higher-margin opportunities.

Haemonetics reported mixed financial results for its fourth quarter and fiscal year ended March 28, 2026. Q4 revenue increased 4.8% to $346.4 million, with adjusted EPS up 4.0% to $1.29, but GAAP EPS showed a loss of $(0.44) due to impairment charges. For the full fiscal year, revenue decreased 2.0% to $1.334 billion, while adjusted EPS reached $4.96. The company also provided fiscal 2027 guidance, projecting reported revenue growth of 4-7% and adjusted operating margin expansion.

Haemonetics Corporation announced that Charles J. Dockendorff will not stand for re-election at the company's 2026 Annual Meeting of Shareholders. Mr. Dockendorff has served on the Board of Directors since 2014 and is currently a member of the Audit Committee and the Governance and Compliance Committee. He will continue in his roles until the 2026 Annual Meeting, and his decision is not due to any disagreement with the company.